AMAbdul Mannan Khan Minhas

Abdul Mannan Khan Minhas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Abdul Mannan Khan Minhas has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association between Oral Beta Blocker Therapy and long-term Outcomes after Myocardial Infarction in Individuals with Mildly Reduced or Preserved Left Ventricular Function – a Meta-Analysis of Contemporary Randomized Controlled Trials

    by Sameer A. Sidiq, Tate A. Truly, Abdul Mannan Khan Minhas, June K. Pickett, John M. Suffredini, Waleed Kayani, Vijay Nambi, Yochai Birnbaum, Xiaoming Jia

    Background In the contemporary reperfusion era, the benefit of beta-blocker therapy in patients after acute myocardial infarction (AMI) and preserved left ventricular ejection fraction (LVEF ≥50%) remains unclear. Recently conducted clinical trials have demonstrated mixed results about the clinical benefit of beta-blockers after myocardial infarction in pooled populations of patients with mildly reduced (LVEF 40–49%) or preserved LVEF. However, new evidence suggests a consistent benefit of beta-blocker therapy in patients specifically with mildly reduced LVEF. We aimed to assess the efficacy of beta-blockers in patients with recent myocardial infarction and mildly reduced or preserved LVEF, as well as specifically with preserved LVEF. Methods We conducted a systematic review of recent randomized controlled trials that evaluated the effects of oral beta-blocker therapy in patients with AMI who had either mildly reduced LVEF or preserved LVEF and with follow-up data of at least 1 year. Using a Mantel-Haenszel random effects model, we computed risk ratios (RR) with 95% confidence intervals for the primary composite outcome along with individual outcomes of death, re-infarction, and heart failure between patients with and without beta-blocker therapy. We performed analysis of the pooled overall study population, which included patients with mildly reduced LVEF and preserved LVEF, as well as performed subgroup analysis of patients with preserved versus mildly reduced LVEF and among men versus women. Results 19,826 patients with mildly reduced or preserved LVEF were included in the meta-analysis. Overall, 9,892 patients were assigned to beta-blockers and 9,934 to no beta-blockers. Among the pooled population, we did not demonstrate significant differences between the beta-blocker group and the control group for the primary composite outcome (RR 0.93, 95% CI 0.83–1.04), all-cause death, reinfarction, or heart failure. We further did not detect differences in the primary outcome by sex. While there was no differences in the primary composite outcome among patients with preserved LVEF (RR 0.96, 95% CI 0.86–1.08), there was reduction in risk observed among individuals with mildly reduced LVEF (RR 0.76, 95% CI 0.61–0.94). Conclusion Oral beta-blocker therapy was not associated with a reduction in the primary composite outcome in patients with preserved LVEF. This contrasts with their established benefit in patients with reduced LVEF and the growing evidence of benefit in those with mildly reduced LVEF.


  • Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions

    by Melody Hermel, Abdul Mannan Khan Minhas, Colin Hinkamp, Maha Inam, Nikitha Murthy, Carly Waldman, Zohar Chai, Vashma Junaid, Adeel Khoja, Sana Sheikh, et al.

    Purpose of Review Focused review highlighting ten select studies presented at the 2024 American Heart Association (AHA) Scientific Sessions. Recent Finding Included studies assessed effects of intensive blood pressure control in patients with type 2 diabetes (BPROAD); decision support system for physicians to optimize early lipid lowering therapies after acute coronary syndrome (ZODIAC); efficacy and safety of zerlasiran, a short interfering RNA targeting lipoprotein(a) (ALPACAR); efficacy and safety of muvalaplin an oral disrupter of the assembly of lipoprotein(a) particles (KRAKEN); safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia (BROOKLYN); efficacy and safety of lerodalcibep, a third generation PCSK9 inhibitor in heterozygous familial hypercholesterolemia subjects (LIBerate-HeFH_OLE); personalized app-based coaching to improve physical activity in patients with HFpEF compared to standard care (MyoMobile); semaglutide to improve cardiovascular outcomes in patients with a history of coronary artery bypass surgery and overweight or obesity (the SELECT trial); efficacy and safety of plozasiran in adults with genetically or clinically defined familial chylomicronemia syndrome at high risk of acute pancreatitis (PALISADE); and transcriptomic signatures and predictors of evolocumab added to maximum statin therapy based on intra-coronary plaque characteristics (YELLOW III). Summary Research presented at the 2024 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.


  • Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions

    by Melody Hermel, Andrew Chiou, Abdul Mannan Khan Minhas, Maha Inam, Carly E. Waldman, Eventine Youngblood, Sandeep Mehta, Leandro Slipczuk, Sana Sheikh, Chelsea Meloche, et al.

    Purpose of Review Focused review highlighting ten select studies presented at the 2023 American Heart Association (AHA) Scientific Sessions. Recent Findings Included studies assessed semaglutide and cardiovascular outcomes in overweight or obese patients without diabetes (SELECT); dapagliflozin in patients with acute myocardial infarction without diabetes (DAPA-MI); effects of dietary sodium on systolic blood pressure in middle-aged individuals (CARDIA-SSBP); long-term blood pressure control after hypertensive pregnancy with physician guided self-management (POP-HT); effect and safety of zilebesiran, an RNA interference therapy, for sustained blood pressure reduction (KARDIA-1); recaticimab add-on therapy in patients with non-familial hypercholesterolemia and mixed hyperlipidemia (REMAIN-2); efficacy and safety of lepodisiran an extended duration short-interfering RNA targeting lipoprotein(a); safety and pharmacodynamic effects of an investigational DNA base editing medicine that inactivates the PCSK9 gene and lowers LDL cholesterol (VERVE-101); automated referral to centralized pharmacy services for evidence-based statin initiation in high-risk patients; and effects of intensive blood pressure lowering in reducing risk of cardiovascular events (ESPRIT). Summary Research presented at the 2023 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.


  • Racial and ethnic disparities in cardiovascular disease - analysis across major US national databases

    by Abdul Mannan Khan Minhas, Khawaja M. Talha, Dmitry Abramov, Heather M. Johnson, Steve Antoine, Fatima Rodriguez, Marat Fudim, Erin D. Michos, Arunima Misra, Layla Abushamat, et al.